Treatment for Low Back Pain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Low Back Pain+2 More
Permanent Epidural Spinal Cord Stimulation - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study whether Spinal Cord Stimulation (SCS) can help reduce blood pressure and pain in patients with chronic low back pain and hypertension.

Eligible Conditions
  • Low Back Pain
  • Hypertension
  • Blood Pressures

Treatment Effectiveness

Study Objectives

5 Primary · 0 Secondary · Reporting Duration: Visit 5 (7-8 weeks post-op)

Visit 2 (intra-op)
Stimulus-Evoked Compound Action Potentials (ECAPS) - Cortex
Spinal Cord
Week 8
Arterial Blood Pressure Change
Laboratory Markers - COMT
Catecholamines

Trial Safety

Trial Design

2 Treatment Groups

Control
1 of 2
Treatment
1 of 2

Active Control

Experimental Treatment

80 Total Participants · 2 Treatment Groups

Primary Treatment: Treatment · No Placebo Group · N/A

Treatment
Device
Experimental Group · 1 Intervention: Permanent Epidural Spinal Cord Stimulation · Intervention Types: Device
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: visit 5 (7-8 weeks post-op)

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,421 Previous Clinical Trials
2,217,773 Total Patients Enrolled
4 Trials studying Low Back Pain
362 Patients Enrolled for Low Back Pain
Marshall Holland, MDPrincipal InvestigatorThe University of Alabama at Birmingham
1 Previous Clinical Trials
20 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to visit a research lab to give blood and/or tissue samples.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: November 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.